Stock Track | Apellis Pharmaceuticals Plummets 5.05% as Mizuho Slashes Price Target

Stock Track11-04

Shares of Apellis Pharmaceuticals Inc. (APLS) took a sharp dive in Monday's intraday trading, plummeting 5.05% following a significant price target cut by a major financial firm. The biotechnology company, which focuses on the development of novel therapeutic compounds, saw its stock come under pressure as investors reacted to the downward revision.

The catalyst for the sell-off was a report from Mizuho, which lowered its target price for Apellis Pharmaceuticals from $24 to $19. This represents a substantial 20.8% reduction in the firm's valuation outlook for the company. The price target cut suggests that Mizuho analysts have become more conservative in their assessment of Apellis's future prospects or valuation.

While the specific reasons behind Mizuho's decision were not immediately clear, such revisions often reflect changes in a company's financial outlook, market conditions, or sector-specific challenges. Investors and market participants will likely be watching closely for any additional analyst comments or company updates that might provide more context to this price target reduction and its potential impact on Apellis Pharmaceuticals' business outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155080466?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 01:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155080466","market":"nz","top_or_hot":-1,"title":"Stock Track | Apellis Pharmaceuticals Plummets 5.05% as Mizuho Slashes Price Target","media":"Stock Track","content":"<p>Shares of Apellis Pharmaceuticals Inc. (APLS) took a sharp dive in Monday's intraday trading, plummeting 5.05% following a significant price target cut by a major financial firm. The biotechnology company, which focuses on the development of novel therapeutic compounds, saw its stock come under pressure as investors reacted to the downward revision.</p>\n\n<p>The catalyst for the sell-off was a report from Mizuho, which lowered its target price for Apellis Pharmaceuticals from $24 to $19. This represents a substantial 20.8% reduction in the firm's valuation outlook for the company. The price target cut suggests that Mizuho analysts have become more conservative in their assessment of Apellis's future prospects or valuation.</p>\n\n<p>While the specific reasons behind Mizuho's decision were not immediately clear, such revisions often reflect changes in a company's financial outlook, market conditions, or sector-specific challenges. Investors and market participants will likely be watching closely for any additional analyst comments or company updates that might provide more context to this price target reduction and its potential impact on Apellis Pharmaceuticals' business outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Apellis Pharmaceuticals Plummets 5.05% as Mizuho Slashes Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Apellis Pharmaceuticals Plummets 5.05% as Mizuho Slashes Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 01:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Apellis Pharmaceuticals Inc. (APLS) took a sharp dive in Monday's intraday trading, plummeting 5.05% following a significant price target cut by a major financial firm. The biotechnology company, which focuses on the development of novel therapeutic compounds, saw its stock come under pressure as investors reacted to the downward revision.</p>\n\n<p>The catalyst for the sell-off was a report from Mizuho, which lowered its target price for Apellis Pharmaceuticals from $24 to $19. This represents a substantial 20.8% reduction in the firm's valuation outlook for the company. The price target cut suggests that Mizuho analysts have become more conservative in their assessment of Apellis's future prospects or valuation.</p>\n\n<p>While the specific reasons behind Mizuho's decision were not immediately clear, such revisions often reflect changes in a company's financial outlook, market conditions, or sector-specific challenges. Investors and market participants will likely be watching closely for any additional analyst comments or company updates that might provide more context to this price target reduction and its potential impact on Apellis Pharmaceuticals' business outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLS","symbol_name":"Apellis Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1155080466","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155080466","pubTimestamp":1762192591,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Apellis Pharmaceuticals Inc. (APLS) took a sharp dive in Monday's intraday trading, plummeting 5.05% following a significant price target cut by a major financial firm. The biotechnology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLS":"Apellis Pharmaceuticals Inc."},"translate_title":"个股追踪|瑞穗下调目标价，Apellis Pharmaceuticals暴跌5.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLS":1},"content_text":"Shares of Apellis Pharmaceuticals Inc. (APLS) took a sharp dive in Monday's intraday trading, plummeting 5.05% following a significant price target cut by a major financial firm. The biotechnology company, which focuses on the development of novel therapeutic compounds, saw its stock come under pressure as investors reacted to the downward revision.\nThe catalyst for the sell-off was a report from Mizuho, which lowered its target price for Apellis Pharmaceuticals from $24 to $19. This represents a substantial 20.8% reduction in the firm's valuation outlook for the company. The price target cut suggests that Mizuho analysts have become more conservative in their assessment of Apellis's future prospects or valuation.\nWhile the specific reasons behind Mizuho's decision were not immediately clear, such revisions often reflect changes in a company's financial outlook, market conditions, or sector-specific challenges. Investors and market participants will likely be watching closely for any additional analyst comments or company updates that might provide more context to this price target reduction and its potential impact on Apellis Pharmaceuticals' business outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155080466","isCrawlerRequest":true}